IRON: Disc Medicine, Inc.
About
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company was founded in October 2017 and is headquartered in Watertown, MA.
Current Value
$59.101 Year Return
Current Value
$59.101 Year Return
Key Details
Market Cap
$1.77B
P/E Ratio
-15
1Y Stock Return
15.07%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
3.8
Strategies that include IRON
Stock's related to IRON
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TEM | 37.76% | $8.50B | 0.00% | 0.00% |
| ZYME | 33.51% | $1.03B | +79.68% | 0.00% |
| KALV | 29.97% | $440.88M | +17.08% | 0.00% |
| GSAT | 29.76% | $3.29B | +19.18% | 0.00% |
| CWCO | 28.39% | $414.24M | -26.08% | 1.51% |
| NGNE | 27.94% | $223.88M | +32.95% | 0.00% |
| IART | 27.61% | $1.77B | -40.82% | 0.00% |
| TRNO | 26.22% | $6.04B | +9.22% | 3.06% |
| BHVN | 26.14% | $4.67B | +56.79% | 0.00% |
| URGN | 25.97% | $470.95M | -11.92% | 0.00% |
| RXRX | 25.66% | $1.80B | -4.13% | 0.00% |
| HIW | 25.64% | $3.34B | +74.29% | 6.42% |
| IDCC | 25.40% | $4.64B | +83.82% | 0.90% |
| PLYM | 25.28% | $842.88M | -11.32% | 5.12% |
| KOD | 24.82% | $296.80M | +150.67% | 0.00% |
| IRT | 24.81% | $4.81B | +60.60% | 3.03% |
| IVT | 24.49% | $2.38B | +27.45% | 2.91% |
| ARCC | 24.30% | $13.45B | - | 8.81% |
| CUZ | 24.28% | $4.89B | +57.48% | 4.17% |
| REXR | 24.04% | $9.55B | -8.36% | 3.81% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CSL | -<0.01% | $19.72B | +59.12% | 0.85% |
| GEV | -0.01% | $93.72B | +159.05% | 0.00% |
| OIS | 0.01% | $336.38M | -24.18% | 0.00% |
| SBLK | -0.02% | $2.38B | +2.30% | 10.64% |
| CBT | 0.03% | $5.91B | +38.59% | 1.54% |
| MSGS | 0.04% | $5.33B | +30.70% | 0.00% |
| AZO | 0.04% | $52.52B | +16.10% | 0.00% |
| FNV | 0.05% | $23.34B | +3.72% | 1.18% |
| VLO | -0.05% | $44.96B | +15.30% | 2.28% |
| MTD | -0.06% | $24.49B | +6.92% | 0.00% |
| NEWT | 0.06% | $364.85M | +5.72% | 5.42% |
| HP | -0.07% | $3.30B | -10.93% | 3.02% |
| GLPG | 0.07% | $1.76B | -27.61% | 0.00% |
| TFII | -0.07% | $12.09B | +24.27% | 1.12% |
| ZH | 0.07% | $333.09M | -40.59% | 0.00% |
| UAL | 0.08% | $31.00B | +139.00% | 0.00% |
| TFC | -0.08% | $61.90B | +47.66% | 4.44% |
| BG | 0.11% | $12.50B | -17.29% | 3.02% |
| KHC | 0.13% | $36.98B | -10.45% | 5.23% |
| PAC | -0.14% | $8.16B | +31.59% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LEU | -16.11% | $1.12B | +33.82% | 0.00% |
| USAP | -15.76% | $412.06M | +176.63% | 0.00% |
| NNVC | -15.17% | $19.66M | +25.69% | 0.00% |
| DMLP | -15.02% | $1.58B | +18.00% | 10.54% |
| TPST | -13.87% | $37.75M | -77.59% | 0.00% |
| PAYS | -13.37% | $176.71M | +37.50% | 0.00% |
| FLNG | -12.84% | $1.42B | -14.21% | 11.33% |
| NAT | -12.60% | $636.83M | -30.05% | 13.79% |
| FRO | -12.02% | $4.56B | -7.37% | 9.36% |
| CCJ | -12.01% | $25.01B | +28.34% | 0.15% |
| DHT | -12.00% | $1.72B | +5.04% | 9.18% |
| GES | -11.39% | $851.55M | -23.98% | 7.30% |
| SVM | -11.25% | $881.13M | +68.75% | 0.71% |
| BCE | -11.01% | $24.91B | -30.63% | 10.69% |
| STNG | -10.59% | $2.96B | +0.87% | 2.75% |
| NYT | -10.53% | $8.54B | +15.47% | 0.96% |
| NOAH | -10.53% | $775.22M | -3.69% | 8.96% |
| PLG | -10.34% | $173.19M | +67.33% | 0.00% |
| LPG | -9.94% | $1.10B | -31.36% | 0.00% |
| BSM | -9.68% | $3.17B | -13.01% | 10.65% |
ETF's related to IRON
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -16.54% | $388.04M | 1.43% |
| VIXY | -12.69% | $195.31M | 0.85% |
| TPMN | -10.81% | $40.60M | 0.65% |
| DBA | -10.80% | $755.88M | 0.93% |
| CANE | -10.40% | $17.72M | 0.29% |
| KRBN | -9.83% | $242.47M | 0.85% |
| URNM | -9.28% | $1.61B | 0.75% |
| KCCA | -9.17% | $220.51M | 0.87% |
| CTA | -8.71% | $350.27M | 0.78% |
| USCI | -8.24% | $185.47M | 1.07% |
| HDRO | -6.90% | $164.26M | 0.3% |
| URNJ | -6.49% | $283.55M | 0.8% |
| UUP | -6.41% | $309.25M | 0.77% |
| TBIL | -6.26% | $4.38B | 0.15% |
| DUSB | -6.06% | $797.63M | 0.15% |
| URA | -6.02% | $3.55B | 0.69% |
| USDU | -6.00% | $201.97M | 0.5% |
| CORN | -5.89% | $61.12M | 0.2% |
| EQLS | -5.80% | $76.08M | 1% |
| FLRN | -5.79% | $2.33B | 0.15% |
News
Yahoo
WATERTOWN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at two upcoming investor conferences: Stifel 2024 Healthcare Conference on Tuesday, November 19th at 8:35 a.m. ET. Jefferies London Healthcare Conference on Thursday, November 21
Yahoo
Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study parameters with the potential for accelerated approval based on existing dataPresented proof-of-mechanism data for Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia at the American Society of Nephrology (ASN) Kidney Week 2024Eight posters and an oral presentation across all three cl
Yahoo
The loan facility comprises up to four tranches, with a $30m tranche already drawn at closing and further funds available through H2 2026.
Finnhub
WATERTOWN - Disc Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious...
Finnhub
Disc Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic...
Yahoo
Oral presentation of complete data from Phase 1b trial of DISC-0974 in anemia of myelofibrosis (MF) Poster presentations across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indicationsManagement will host a conference call during the ASH meeting on Sunday, December 8 at 9:00pm EST / 6:00pm PST WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.